Hematologic immune-related adverse events in skin cancer patients treated with immune checkpoint inhibitors: a case series.

ABSTRACT:

Background

Immune checkpoint inhibitors (ICIs) are the gold standard therapy for cutaneous melanoma and are also used effectively in treating other types of skin cancer. Hematologic toxicities are rare, but potentially a serious and life-threatening side effect of ICIs. Clinical and biological biomarkers able to predict these events have been poorly explored and have not yet been identified.

Case presentation

We present four cases of hematologic toxicity in melanoma patients and one case in a patient with cutaneous squamous cell carcinoma, all of which arose during treatment with ICIs in an adjuvant or metastatic setting. Hemolytic anemia was the most frequent event; neutropenia with agranulocytosis happened in one case and was fatal. ICI treatment was discontinued in all fi

SUBMITTER: Falcone R 

PROVIDER: S-EPMC12816168 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature